



OPEN ACCESS

High prevalence of medication use in professional football tournaments including the World Cups between 2002 and 2014: a narrative review with a focus on NSAIDs

Philippe M Tscholl,^{1,2} Martin Vaso,³ Alexis Weber,³ Jiri Dvorak^{1,3}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjsports-2015-094784>).

¹FIFA—Medical Assessment and Research Center (F-MARC), Schulthess Clinic, Zürich, Switzerland

²Division of Orthopedics and Trauma Surgery, Geneva University Hospital, Switzerland

³Fédération Internationale de Football Association, Zürich, Switzerland

Correspondence to

Dr Jiri Dvorak, Fédération Internationale de Football Association (FIFA), FIFA-Strasse 20, Zürich CH-8044, Switzerland; jiri.dvorak@f-marc.com

Accepted 9 March 2015

ABSTRACT

The use of medication in international football has been monitored since the 2002 FIFA World Cup. Team physicians were asked to provide information on prescribed medication 72 h prior to each match for every player. 69% of adult male players reported using medication, with more than half the players using non-steroidal anti-inflammatory drugs (NSAIDs). Up to one-third of all players used NSAIDs prior to every match, regardless of whether they took the field or not. The mean intake of medication was significantly higher during the FIFA Women's World Cup (0.85 vs 0.77 substances per player and per match in men, $p < 0.001$), whereas the use of NSAIDs was similar to that for men. In the Under-20 and Under-17 male competitions, the use of medication was lower as 60% of players used some kind of medication and 43% of the players used NSAIDs during the tournaments. Despite the potential side effects of medication, especially of NSAIDs in the recovery process after a sports activity, there is no evidence of decreasing intake. The reported incidence is alarming, and moreover is most probably underestimated, since self-medication by the players or treatment already prescribed by club physicians is not included in the published reports. Future studies should focus on the daily dosage, time of treatment and especially the medical indication for painkilling agents to better understand the underlying factors.

INTRODUCTION

The FIFA Medical Assessment and Research Centre (F-MARC) was the first medical governing body in international sports to systematically document the use of medication; it has done so since the 1998 FIFA World Cup. For FIFA tournaments, data are collected in connection with doping control after each match. Team physicians are asked to provide information about “any medication taken by the players or administered to them in the 72 hours preceding the match ... The team doctor shall also note down, on the basis of the information at his disposal, medications and food supplements taken by the players without medical prescription”.¹

Other sports governing bodies such as the IOC and the International Association of Athletics Federations (IAAF) followed suit but only for athletes selected for doping control.^{2–5}

For this review, we present published data from 10 men's, women's and male adolescent FIFA World Cups^{6–8} (see [table 1](#)) and compare them with reports from other sports. This review, and

the discussion of overmedication, should be viewed in the context of international campaigns warning against the harms of excessive medication.⁹

The 2002, 2006, 2010 and 2014 FIFA World Cups

The mean intake of medication in male professional football is consistent for all World Cups with 0.77 substances per player and per match (see [table 1](#)). The most frequently prescribed substance group was non-steroidal anti-inflammatory drugs (NSAIDs; see [figure 1](#)), representing 36% of all substances. β -2-Agonists were reported in 44 players (1.2% of all substances, see [table 2](#)) during the four tournaments. However, since β -2-agonists are usually taken during the entire season and do not require a therapeutic use exemption anymore, a national team physician might ignore its use in some players. The use of medication over time did not change significantly, neither in the amount nor in its distribution of substance groups.

FIFA Women's World Cup and the Under-17 and Under-18 FIFA World Championships

The reported use of medication during the 2003 and 2007 FIFA Women's World Cup was significantly higher than in the Men's World Cups (0.85 vs 0.77, $p \leq 0.001$) and than in adolescent football players participating in Under-17 (U-17) and U-20 tournaments (0.51, $p \leq 0.001$; see [table 1](#)). Contraceptive agents were not included in the analysis. Whereas the incidence of the use of NSAIDs was similar between adult male and female players, significantly fewer NSAIDs were administered to adolescent players, suggesting increased consumption with age (see [table 2](#)).

In 14.9% of female players, oral contraceptive use was reported. This is less than what was reported by Alaranta *et al*¹⁰ for other team sport events (24%), and especially in speed, power and endurance events (40%).

NSAIDs and other analgesics

The NSAIDs category was the one that was most reported in every tournament (see [figure 1](#)). In total 54.5% of male players and 50.9% of female players participating in the FIFA World Cup used an NSAID at least once during the tournament; 43.3% adolescent players did so too. Hence, on average, more than seven male and female players per national team were using NSAIDs prior to every match, as were 4.5 players in U-17 and U-20 tournaments (see [table 2](#)). Ten per cent of the male



Open Access
Scan to access more
free content



CrossMark

To cite: Tscholl PM, Vaso M, Weber A, *et al*. *Br J Sports Med* 2015;**49**:580–582.

Table 1 Tournament information

Tournament	Teams (n)	Players (n)	Matches (n)	Reports (n)	Medications prescribed (n)	Intake of medication (per player, per match)
WC 2014	32	736	64	2944	2346	0.80
WC 2010	32	736	64	2944	2335	0.79
WC 2006	32	736	64	2944	2052	0.70
WC 2002	32	736	64	2944	2392	0.81
W-WC 2007	16	336	32	1344	1200	0.89
W-WC 2003	16	320	32	1280	1036	0.81
U-20 2007	24	504	52	2184	965	0.44
U-20 2005	24	504	52	2184	1248	0.57
U-17 2007	24	504	52	2184	1036	0.47
U-17 2005	16	320	32	1280	717	0.56
Total	248	5432	508	22 232	15 327	0.71

U, under; W-WC, Women's World Cup.

and female players were using more than one type of NSAIDs at one time, thus increasing the risk of side effects.

There was no difference in use of medication and NSAIDs, in particular between players participating in the match and substitutes who did not play at all; nor was there a correlation between injuries reported and reported use of medication.⁷ The most frequently prescribed application form was the oral route (93%). In only 7%, NSAIDs were administered topically,⁶ although percutaneous application of NSAIDs might be as efficient as oral preparation in the treatment of soft-tissue injuries.^{11 12}

Other analgesics (such as paracetamol (acetaminophen) and metamizol) were rarely used (5.4% of all substances), although they might be as efficient as NSAIDs in treating postexercise pain. Acetylsalicylic acid accounted for 2.8% of all painkilling agents (NSAIDs, analgesics and myorelaxants) in adolescent players as well as in 2.3% of female adults and 1.2% of male adult football players. As its anti-inflammatory and painkilling functions are weak and it carries an increased risk for traumatic haemorrhage, acetylsalicylic acid is not suitable for use in sports medicine.

Injections with local anaesthetics or corticosteroids were mostly intra-articular, followed by intramuscular applications.⁸ They were performed in almost 8% of all players participating in adult male tournaments, and in about 3% of female adults and male adolescent football players (see table 2). The amount of administration seems to depend highly on the national team physician. Whereas 23 of 32 team physicians did not perform any injections for musculoskeletal symptoms during the 2014 World Cup,⁸ four players from one national team received

peritendinous or intra-articular glucocorticoid injections prior to almost every match. The indication for these injections was not reported. Nevertheless, such repetitive practice during a tournament prior to each match is questionable since the long-term safety of intra-articular application may substantially worsen the injury if play is resumed immediately.¹³

The medical team (ie, likely team physician) was an important influence as to the use of medication. As reported in the 2002 FIFA World Cup, one country reported using more than one type of NSAID per player per match throughout the tournament. Also, allopurinol—a gout medication reducing uric acid but thought to prevent skeletal and cardiac muscle damage¹⁴—was prescribed to 40% of the players from one country during the tournament.

The high use of medication and NSAIDs in particular is not limited to international football. Similar use of medication has been reported during the Sydney Olympics in 2000,² in top-level track and field athletes,⁵ triathletes¹⁵ and also in collegiate athletes.^{16 17} An unpublished review¹⁸ of articles published between 2003 and 2010^{3-7 10 17 19} found that power/sprint disciplines show a similar 'substance profile' as ball sports.

Although endurance athletes rarely used NSAIDs (6.8%±0.2 vs 27.3%±0.4 in power/sprint disciplines), their declared use of corticosteroids (15.0%±0.3 vs 4.6%±0.1) and β-2-agonists (6.8±0.2 vs 2.3%±0.1) increased significantly (p<0.05). In popular events such as the Bonn Marathon 2009,²⁰ Berlin Marathon 2010²¹ and El Andalus Ultramarathon,²² 47–61% of athletes used NSAIDs or other painkilling agents. The participants using NSAIDs had an almost five times higher incidence of adverse events (gastrointestinal cramps and bleeds,




Figure 1 Prescribed medication during the FIFA World Cup. N=9124 for the 2002, 2006, 2010 and 2014 FIFA World Cups; N=2236 for the 2003 and 2007 FIFA Women's World Cup; N=3966 for the 2005 and 2007 FIFA U-17/U-20 World Championships (NSAIDs, non-steroidal anti-inflammatory drugs; U, under; W-WC, Women's World Cup).

Table 2 Number of players using a substance prior to a match or during the tournament

	2002–2014 FIFA WC Players (n)				2003–2007 FIFA Women's WC Players (n)				2005–2007 FIFA U-17/U-20 WC Players (n)			
	Per match		During the tournament		Per match		During the tournament		Per match		During the tournament	
	(N=11 776)	Per cent	(n=2944)	Per cent	(N=2624)	Per cent	n=656	Per cent	N=7831	Per cent	n=1832	Per cent
Any medication	5179	44.0	2029	68.9	1315	50.1	469	71.5	2644	33.8	1097	59.9
NSAIDs	3737	31.7	1604	54.5	806	30.7	334	50.9	1534	19.6	793	43.3
Injections*	422	3.6	234	7.9	32	1.2	18	2.7	89	1.1	49	2.7
Analgesics	588	5.0	376	12.8	143	5.4	95	14.5	188	2.4	137	7.5
β-2-Agonists	142	1.2	44	1.5	104	4.0	28	4.3	77	1.0	24	1.3
Myorelaxants	395	3.4	225	7.6	25	1.0	23	3.5	294	3.8	20	1.1
Any supplement	2985	25.3	984	33.4	880	33.5	229	45.6	3104	39.6	906	49.5

*Injections of corticosteroids and/or anaesthetics.

NSAID, non-steroidal anti-inflammatory drugs; U, under; WC, World Cup.

haematuria or cardiovascular events, such as arrhythmia and palpitation), which increased significantly with the analgesic dosage. It is noteworthy that serious adverse events occurred only in patients who were using NSAIDs (3 athletes with oliguria/anuria using ibuprofen, and 4 gastric bleeds, all using 500–1000 mg acetylsalicylic acid).²¹ It is alarming that most athletes are not aware of the potentially deleterious adverse effects of NSAIDs after strenuous exercise, and that physicians are rarely asked for advice prior to its use.^{16 20–23}

The routine use of NSAIDs in sport is harmful in the short term and potentially also in the long term. Owing to its anti-inflammatory effect, NSAIDs delay bone healing,^{24 25} decrease protein synthesis and inhibit peritendinous hyperaemia and satellite cells in skeletal muscle after exercise.^{26–28} A randomised controlled trial has shown that NSAIDs permit earlier mobilisation, weight bearing and return to play compared with placebo after ankle sprains. However, there are also reports of more swelling, an increased incidence of residual instability and a decreased range of motion in ankles.²⁹ This might be due to lower load-to-failure properties of the 'healed' ligament after the use of NSAIDs.³⁰ Also, DOMS (delayed onset of muscle soreness) can be treated with NSAIDs to reduce pain and enable earlier return to play. However, accompanying muscle weakness and imbalance are not improved. A precipitate return to sport before muscular balance is re-established might put the player at risk for inappropriate biomechanical stress and overuse injuries.^{31 32}

Knowledge translation and important questions

F-MARC campaigned to reduce the use of NSAIDs prior to the 2010 FIFA World Cup by informing all team physicians about NSAIDs and their potential side effects on recovery processes after exercise bouts and on tissue healing. Despite this initiative, the reported intake of NSAIDs remained unchanged in 2010 and 2014.

Our review poses several salient questions: What is the indication for which one-third of players use NSAIDs prior to every match, particularly when this greatly exceeds the rate of reported injuries during the FIFA World Cup? Is the high prescription practice due to a high number of non-time loss, chronic and overuse injuries?³³ Are painkilling medications used routinely by the players to overcome fatigue and muscle soreness due to physical overload, or even improve recovery? Or has it simply become 'part of the game' for players and team physicians?

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- 1 FIFA, Fédération Internationale de Football Association. FIFA Anti-Doping Regulations. 2015. http://www.fifa.com/mm/document/footballdevelopment/medical/01/17/17/09/anti-doping_neutral.pdf (accessed 1 Mar 2015).
- 2 Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). *Clin J Sports Med* 2003;13:33–40.
- 3 Tsitsimpikou C, Tsiokanos A, Tsarouhas K, et al. Medication use by athletes at the Athens 2004 Summer Olympic Games. *Clin J Sports Med* 2009;19:33–8.
- 4 Thuyne WV, Delbeke FT. Declared use of medication in sports. *Clin J Sports Med* 2008;18:143–7.
- 5 Tscholl P, Alonso JM, Dolle G, et al. The use of drugs and nutritional supplements in top-level track and field athletes. *Am J Sports Med* 2010;38:133–40.
- 6 Tscholl P, Feddermann N, Junge A, et al. The use and abuse of painkillers in international soccer: data from 6 FIFA tournaments for female and youth players. *Am J Sports Med* 2009;37:260–5.
- 7 Tscholl P, Junge A, Dvorak J. The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006. *Br J Sports Med* 2008;42:725–30.
- 8 Tscholl PM, Dvorak J. Abuse of medication during international football competition in 2010—lesson not learned. *Br J Sports Med* 2012;46:1140–1.
- 9 Moynihan R, Heneghan C, Godlee F. Too much medicine: from evidence to action. *BMJ* 2013;347:f7141.
- 10 Alaranta A, Alaranta H, Heliövaara M, et al. Ample use of physician-prescribed medications in Finnish elite athletes. *Int J Sports Med* 2006;27:919–25.
- 11 Efe T, Sagnak E, Roessler PP, et al. Penetration of topical diclofenac sodium 4% spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. *Knee Surg Sports Traumatol Arthrosc* 2014;22:345–50.
- 12 Kuehl KS. Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries. *Clin Ther* 2010;32:1001–14.
- 13 Orchard JW, Steet E, Massey A, et al. Long-term safety of using local anesthetic injections in professional rugby league. *Am J Sports Med* 2010;38:2259–66.
- 14 Sanchis-Gomar F, Pareja-Galeano H, Gomez-Cabrera MC, et al. Allopurinol prevents cardiac and skeletal muscle damage in professional soccer players. *Scand J Med Sci Sports* 2015;25:e110–15.
- 15 Wharam PC, Speedy DB, Noakes TD, et al. NSAID use increases the risk of developing hyponatremia during an Ironman triathlon. *Med Sci Sports Exerc* 2006;38:618–22.
- 16 Holmes N, Cronholm PF, Duffy AJ III, et al. Nonsteroidal anti-inflammatory drug use in collegiate football players. *Clin J Sports Med* 2013;23:283–6.
- 17 Warner DC, Schnepf G, Barrett MS, et al. Prevalence, attitudes, and behaviors related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in student athletes. *J Adolesc Health* 2002;30:150–3.
- 18 Tscholl PM, Alonso JM, Junge A, et al. *Risk factors for the use of medication in elite athletes*. Paper presented at: Oslo: ECSS, 2009.
- 19 Huang SH, Johnson K, Pipe AL. The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games. *Clin J Sports Med* 2006;16:27–33.

- 20 Brune K, Niederweis U, Kaufmann A, *et al.* [Drug use in participants of the Bonn Marthon 2009]. *MMW Fortschr Med* 2009;151:39–41.
- 21 Küster M, Renner B, Oppel P, *et al.* Consumption of analgesics before a marathon and the incidence of cardiovascular, gastrointestinal and renal problems: a cohort study. *BMJ Open* 2013;3:e002090.
- 22 Scheer BV, Murray A. Al Andalus Ultra Trail: an observation of medical interventions during a 219-m, 5-day ultramarathon stage race. *Clin J Sports Med* 2011;21:444–6.
- 23 Gorski T, Cadore EL, Pinto SS, *et al.* Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use. *Br J Sports Med* 2011;45:85–90.
- 24 Bergenstock M, Min W, Simon AM, *et al.* A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. *J Orthop Trauma* 2005;19:717–23.
- 25 Giannoudis PV, MacDonald DA, Matthews SJ, *et al.* Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. *J Bone Joint Surg Br* 2000;82:655–8.
- 26 Kjaer M, Bayer ML, Eliasson P, *et al.* What is the impact of inflammation on the critical interplay between mechanical signaling and biochemical changes in tendon matrix? *J Appl Physiol* 2013;115:879–83.
- 27 Trappe TA, White F, Lambert CP, *et al.* Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. *Am J Physiol Endocrinol Metab* 2002;282:E551–6.
- 28 Mackey AL. Does an NSAID a day keep satellite cells at bay? *J Appl Physiol* 2013;115:900–8.
- 29 Slatyer MA, Hensley MJ, Lopert R. A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. *Am J Sports Med* 1997;25:544–53.
- 30 Elder CL, Dahners LE, Weinhold PS. A cyclooxygenase-2 inhibitor impairs ligament healing in the rat. *Am J Sports Med* 2001;29:801–5.
- 31 Lewis PB, Ruby D, Bush-Joseph CA. Muscle soreness and delayed-onset muscle soreness. *Clin Sports Med* 2012;31:255–62.
- 32 Mackey AL, Mikkelsen UR, Magnusson SP, *et al.* Rehabilitation of muscle after injury—the role of anti-inflammatory drugs. *Scan J Med Sci Sports* 2012;22:e8–14.
- 33 Clarsen B, Myklebust G, Bahr R. Development and validation of a new method for the registration of overuse injuries in sports injury epidemiology: the Oslo Sports Trauma Research Centre (OSTRC) overuse injury questionnaire. *Br J Sports Med* 2013;47:495–502.